{
  "id": "39955543-0bae-479c-8f22-518b7c94beeb",
  "title": "Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products",
  "link": "https://seekingalpha.com/news/4409800-halozyme-projects-1_15b-1_225b-revenue-for-2025-with-growth-from-key-products?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Tue, 18 Feb 2025 19:55:50 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "halo"
  ],
  "byline": "SA Transcript Insights Editor",
  "length": 1110,
  "excerpt": "Halozyme Therapeutics' record-breaking 2024 revenue exceeded $1B, with strong 2025 growth projections led by DARZALEX \u0026 VYVGART.",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Earnings Call Insights: Halozyme Therapeutics (NASDAQ:HALO) Q4 2024 Management View CEO Helen Torley highlighted record-breaking performance in 2024, with total revenue surpassing $1 billion, a 22% year-over-year growth. Key milestones included approvals for four major products or indications using ENHANZE, patent extensions in Europe, and five new Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.",
  "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003c/header\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cp\u003eEarnings Call Insights: Halozyme Therapeutics (\u003cspan\u003eNASDAQ:\u003ca href=\"https://seekingalpha.com/symbol/HALO\" title=\"Halozyme Therapeutics, Inc.\"\u003eHALO\u003c/a\u003e\u003c/span\u003e) Q4 2024\u003c/p\u003e \u003ch3\u003eManagement View\u003c/h3\u003e \u003cul\u003e \u003cli\u003eCEO Helen Torley highlighted record-breaking performance in 2024, with total revenue surpassing $1 billion, a 22% year-over-year growth. Key milestones included approvals for four major products or indications using ENHANZE, patent extensions in Europe, and five new\u003c/li\u003e \u003c/ul\u003e\u003c/div\u003e\u003cp\u003e\u003cstrong\u003eSeeking Alpha\u0026#39;s Disclaimer: \u003c/strong\u003eThe earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts \u003ca href=\"https://seekingalpha.com/symbol/HALO/earnings/transcripts\"\u003ehere\u003c/a\u003e. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "2 min read",
  "publishedTime": "2025-02-19T00:55:50Z",
  "modifiedTime": null
}
